Cytotoxicity of PAI2, C595 and Herceptin vectors labeled with the alpha-emitting radioisotope Bismuth-213 for ovarian cancer cell monolayers and clusters

Cancer Letters

Volumn 234, Issue 2, 2006, Pages 176-183

  Song, Yan J ^a,b   Qu, Chang F ^a,b   Rizvi, Syed M A ^a   Li, Yong ^a   Robertson, G ^a,b   Raja, Chand ^a   Morgenstern, Alfred ^c   Apostolidis, Christos ^c   Perkins, Alan C ^d   Allen, Barry J ^a,b  

^a ST GEORGE HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c JOINT RESEARCH CENTRE   (Italy)

^d QUEEN S MEDICAL CENTRE   (United Kingdom)

Author keywords

Bismuth 213; HER2; MUC1; Ovarian cancer cell line; Radioimmunotherapy; uPA

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY C595 BI 213; MUCIN 1; NCRC 48; PLASMINOGEN ACTIVATOR INHIBITOR 2 BI 213; RADIOPHARMACEUTICAL AGENT; TRASTUZUMAB BI 213; UNCLASSIFIED DRUG; UROKINASE;

ALPHA RADIATION; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CELL STRUCTURE; CHELATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; HUMAN; HUMAN CELL; ISOTOPE LABELING; MINIMAL RESIDUAL DISEASE; MONOLAYER CULTURE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; RECEPTOR UPREGULATION;

ALPHA PARTICLES; ANTIBODIES, MONOCLONAL; BISMUTH; CA-15-3 ANTIGEN; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; PLASMINOGEN ACTIVATOR INHIBITOR 2; RADIOISOTOPES; RECEPTOR, ERBB-2; SPHEROIDS, CELLULAR; TUMOR CELLS, CULTURED; URINARY PLASMINOGEN ACTIVATOR;

EID: 33645013588     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.03.060     Document Type: Article

References (25)

1. G. Bolis, A. Villa, P. Guarnerio, C. Ferraris, N. Gavoni, and G. Giardina Survival of women with advanced ovarian cancer and complete pathologic response at second-look laparotomy Cancer 77 1 1996 128 131
2. B.J. Allen Targeted alpha therapy: evidence for potential efficacy of alpha-immunoconjugates in the management of micrometastatic cancer Australasian Radiology 43 4 1999 480 486
3. D.A. Scheinberg, M. Strand, and O.A. Gansow Tumor imaging with radioactive metal chelates conjugated to monoclonal antibodies Science 215 4539 1982 1511 1513
4. B.J. Allen Can alpha-immunotherapy succeed where other systemic modalities have failed? Nuclear Medicine Communications 20 3 1999 205 207
5. M.R. McDevitt, E. Barendswaard, D. Ma, L. Lai, M.J. Curcio, and G. Sgouros An alpha-particle emitting antibody Cancer Research 60 21 2000 6095 6100
6. P.A. Andreasen, R. Egelund, and H.H. Petersen The plasminogen activation system in tumor growth, invasion, and metastasis Cellular & Molecular Life Sciences 57 1 2000 25 40
7. E.K. Kruithof, M.S. Baker, and C.L. Bunn Biological and clinical aspects of plasminogen activator inhibitor type 2 Blood 86 11 1995 4007 4024
8. M.R. Price, J.A. Pugh, F. Hudecz, W. Griffiths, E. Jacobs, and I.M. Symonds C595-a monoclonal antibody against the protein core of human urinary epithelial mucin commonly expressed in breast carcinomas British Journal of Cancer 61 5 1990 681 686
9. S. Gendler, J. Taylor-Papadimitriou, T. Duhig, J. Rothbard, and J. Burchell A highly immunogenic region of a human polymorphic epithelial mucin expressed by carcinomas is made up of tandem repeats Journal of Biological Chemistry 263 26 1988 12820 12823
10. J.Y. Wang, C.T. Chang, J.S. Hsieh, L.W. Lee, T.J. Huang, and C.Y. Chai Role of MUC1 and MUC5AC expressions as prognostic indicators in gastric carcinomas Journal of Surgical Oncology 83 4 2003 253 260
11. M.V. Croce, M.T. Isla-Larrain, C.E. Rua, M.E. Rabassa, S.J. Gendler, and A. Segal-Eiras Patterns of MUC1 tissue expression defined by an anti-MUC1 cytoplasmic tail monoclonal antibody in breast cancer Journal of Histochemistry & Cytochemistry 51 6 2003 781 788
12. J. Teruya-Feldstein, G.B. Donnelly, A. Goy, A. Hegde, G. Nanjangud, and J. Qin MUC-1 mucin protein expression in B-cell lymphomas Applied Immunohistochemistry & Molecular Morphology 11 1 2003 28 32
13. H. Feng, M. Ghazizadeh, H. Konishi, and T. Araki Expression of MUCl and MUC2 mucin gene products human ovarian carcinomas Japanese Journal of Clinical Oncology 32 12 2002 525 529
14. I. Brockhausen, J.M. Yang, J. Burchell, C. Whitehouse, and J. Taylor-Papadimitriou Mechanisms underlying aberrant glycosylation of MUCl mucin in breast cancer cells European Journal of Biochemistry 233 2 1995 607 617
15. I. Hellstrom, G. Goodman, J. Pullman, Y. Yang, and K.E. Hellstrom Overexpression of HER-2 in ovarian carcinomas Cancer Research 61 6 2001 2420 2423
16. P. Carter, L. Presta, C.M. Gorman, J. Ridgway, and W.L. Wong Humanization of an anti-p185HER2 antibody for human cancer therapy Proceedings of the National Academy of Sciences of the United States of America 89 10 1992 4285 4289
17. C. Borgfeldt, P.O. Bendahl, B. Gustavsson, E. Langstrom, M. Ferno, and R. Willen High tumor tissue concentration of urokinase plasminogen activator receptor is associated with good prognosis in patients with ovarian cancer Intemational Journal of Cancer 107 4 2003 658 665
18. G. Konecny, M. Untch, A. Pihan, R. Kimmig, M. Gropp, and P. Stieber Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer Clinical Cancer Research 7 6 2001 1743 1749
19. R.L. Giuntoli 2nd, G.C. Rodriguez, R.S. Whitaker, R. Dodge, and J.A. Voynow Mucin gene expression in ovarian cancers Cancer Research 58 23 1998 5546 5550
20. I. Skirnisdottir, B. Sorbe, and T. Seidal The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma International Journal of Gynecological Cancer 11 2 2001 119 129
21. T.S. Marian, and G. Rainaldi Three-dimensional spheroid model in tumor biology Pathbiology 67 1999 148 157
22. S.J. Griffiths, P.F. Heelis, A.K. Haylett, and J.V. Moore Photodynamic therapy of ovarian tumours and normal cells using 5,10,15,20-tetra-(3- carboxymethoxyphenyl)-chlorin Cancer Letters 125 l-2 1998 177 184
23. S.M. Abbas Rizvi, S. Sarkar, G. Goozee, and B.J. Allen Radioimmunoconjugates for targeted alpha therapy of malignant melanoma Melanoma Research 10 3 2000 281 289
24. Y. Li, S.M. Rizvi, M. Ranson, and B.J. Allen 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model British Journal of Cancer 86 7 2002 1197 1203
25. R.M. Macklis, J.Y. Lin, B. Beresford, R.W. Atcher, J.J. Hines, and J.L. Humm Cellular kinetics, dosimetry, and radiobiology of alpha-particle radioimmunotherapy: induction of apoptosis Radiation Research 130 2 1992 220 226